AI Agents for Faster Drug Advancement Decisions

After Phase 1 trials, every drug candidate reaches a go/no-go point: does it show enough potential to justify the next phase of development? In a regulated industry, that decision weighs many variables at once. They include early clinical signals, the patient population, the competitive landscape, commercial potential, and the cost and risk of the next phase.

Getting the call right, and making it quickly, matters. Advancing a weak candidate ties up resources that could go to stronger ones. Slow decisions delay promising therapies on their way to patients.

The bottleneck was the analysis loop. Teams preparing a candidate’s case averaged about 2.3 review cycles before a decision, because reviewers kept finding gaps that sent the case back. Each cycle added time to the decision and pulled teams away from the science.

Two AI agents that work before the decision review, so issues are caught before the case reaches reviewers.

• Readiness agent Shows teams what a strong advancement case needs, including the evidence, analyses and structure reviewers expect. Before anything goes to the committee, it checks the submitted data for thoroughness and compares the full submission against a checklist we developed, so every component of the candidate’s business case profile is present. New teams get up to speed faster and first submissions arrive complete.
• Review simulation agent Stress-tests a draft case against the questions the decision committee is likely to raise. Teams close the gaps before review instead of after it.

• Program teams Fewer rework cycles and more time on the analysis that moves a candidate forward.
• Decision-makers Cases arrive complete and already stress-tested, so reviews focus on the decision itself.
• The pipeline Faster, better-informed calls on which candidates advance, so resources reach the most promising ones sooner.

• Reframed the ask. Stakeholders came asking for a specific agent. I took them back to the problem and found the real cost: repeated review cycles, not the single step they had named.
• Set success criteria before building. I defined measurable targets up front, so the proof of concept had to show value before any larger investment.
• Ran it in gated phases. Define & Align → Build & Integrate → Deploy. Engineering started each phase only after the business had confirmed alignment, which kept the build stable.
• Built in ground truth. Decision committee members reviewed the issues the agents flagged and confirmed whether they were real. That measured accuracy, not just usage.